In acute myeloid leukemia (AML), for example, where elevated expression of miR-10a is reported, the levels of this microRNA serve as a predictive biomarker for sensitivity to the emerging mouse double minute 2 (MDM2) inhibition therapy which in turn reactivates the already functional but suppressed P53 [81]. Here, MDM2 is linked to acute myeloid leukemia.